This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McDougal, A. Articles by Safe, S. Search for Related Content PubMed PubMed Citation Articles by McDougal, A. Articles by Safe, S.

Tamoxifen-induced Antitumorigenic/Antiestrogenic Action Synergized by a Selective Aryl Hydrocarbon Receptor Modulator¹

Departments of Veterinary Physiology and Pharmacology [A. M., M. W., S. S.] and Statistics [J. C.], Texas A&M University, College Station, Texas 77843

Tamoxifen (TAM) is a highly effective selective estrogen receptor (ER) modulator used extensively for the treatment and prevention of breast cancer. However, prolonged treatment of women with TAM may be a risk factor for endometrial cancer, and research in our laboratory is focused on the development of selective aryl hydrocarbon receptor modulators that can be used in combination with TAM to improve its efficacy in the breast and inhibit TAM-induced endometrial effects. This study investigated the effects of the selective aryl hydrocarbon receptor modulators 6-methyl-1,3,8-trichlorodibenzofuran (6-MCDF) alone and in combination with TAM in the carcinogen-induced mammary tumor model and in the ovariectomized uterotropic assay using female Sprague Dawley rats. The lowest effective dose of 6-MCDF that inhibited tumor growth was 50 µg/kg/day, and TAM was antitumorigenic at a dose of 100 µg/kg/day. In animals cotreated with TAM + 6-MCDF at doses of 100, 50, or 25 µg/kg/day of each compound, complete inhibition of mammary tumor growth was observed at all doses, and the results are consistent with a more than additive antitumorigenic response for the low dose group (25 + 25 µg/kg) and additive interactions at the 50 and 100 µg/kg doses. In a separate experiment, 6-MCDF (800 µg/kg) inhibited TAM-induced peroxidase activity and progesterone receptor binding in the ovariectomized rat uterus but did not affect TAM-induced bone growth in ovariectomized rats. This study also investigated the effects of TAM and 6-MCDF alone and in combination on ER protein levels in MCF-7 human breast cancer cells as a model for studying interactions between these compounds. The results show that 6-MCDF decreased TAM-induced ER levels in the absence or presence of 17ß-estradiol through proteasome activation, and these interactions may contribute to the observed combined antitumorigenic effects of these compounds.

This article has been cited by other articles:

				M. Pervan, K. S. Iwamoto, and W. H. McBride Proteasome Structures Affected by Ionizing Radiation Mol. Cancer Res., July 1, 2005; 3(7): 381 - 390. [Abstract] [Full Text] [PDF]

				S. T. Pearce, H. Liu, I. Radhakrishnan, M. Abdelrahim, S. Safe, and V. C. Jordan Interaction of the Aryl Hydrocarbon Receptor Ligand 6-Methyl-1,3,8-trichlorodibenzofuran with Estrogen Receptor {alpha} Cancer Res., April 15, 2004; 64(8): 2889 - 2897. [Abstract] [Full Text] [PDF]